Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Since its original isolation in 2009, Candida auris has spread across the globe as a causative agent of invasive candidiasis. C. auris is typically intrinsically resistant to fluconazole and can also be resistant to echinocandins and even amphotericin B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“In a recent retrospective review of the clinical history of 54 patients, most had multiple risk factors for invasive disease, and candidemia was observed in 61% (8).”
BackgroundSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.141 · Cited by 1,041
Self-citationSecular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768 · cited 1×
“auris infections in London from April 2015 to July 2016 had 50 cases, with 44% of patients developing candidemia, and strict infection and prevention control measures had to be implemented to slow hospital transmission (12, 13).”
BackgroundChowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Sherry, L., Ramage, G., Kean, R., Borman, A., Johnson, E. M., Richardson, M. D., & Rautemaa-Richardson, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161320 · Cited by 420
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris
Chatterjee, S., Alampalli, S. V., Nageshan, R. K., Chettiar, S. T., Joshi, S., & Tatu, U. S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1863-z · Cited by 247 · cited 1×
“To make matters worse, this species is also often misidentified by commercially available automated systems that use biochemical means for species identification (20, 21).”
BackgroundSharma, C., Kumar, N., Pandey, R., Meis, J. F., & Chowdhary, A. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.07.003 · Cited by 202
Antifungal therapy with an emphasis on biofilms
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.008 · Cited by 173 · cited 1×
“form biofilms on inert and biological surfaces, and biofilm formation further complicates treatment due to the high levels of resistance against most clinically used antifungals (49).”
BackgroundAbdolrasouli, A., Armstrong‐James, D., Ryan, L., & Schelenz, S. (2017) · Mycoses · doi:10.1111/myc.12699 · Cited by 150
Candida auris : An emerging multidrug-resistant pathogen
Sears, D., & Schwartz, B. S. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.08.017 · Cited by 146 · cited 1×
“auris, its spread, and the increasing number of infections caused by this recently described pathogen (23, 24).”
BackgroundSiles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-13 · Cited by 120 · cited 1×
“novel functionality of the established molecule (27).”
Self-citation
Cited by
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Lara, H. H., Ixtepan-Turrent, L., Jose Yacaman, M., & Lopez-Ribot, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20708 · Cited by 116
Self-citationKim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110812 · Cited by 71
“com/ Candida species, Cryptococcus species, Saccharomyces cerevisiae, Aspergillus fumigatus, Fusarium oxysporum, Fusarium solani, Lichtheimia species, Lomentospora prolificans, Paecilomyces variotii, Rhizopus arrhizus, Scedosporium apiospermum [23,25,66,75,83,94,96,124, 165,228]”
BackgroundVila, T., Montelongo-Jauregui, D., Ahmed, H., Puthran, T., Sultan, A. S., & Jabra-Rizk, M. A. (2020) · mSphere · doi:10.1128/msphere.00760-20 · Cited by 58
“One unique growth feature in some isolates is cell aggregation (17) which was associated in vitro with differences in drug susceptibility, biofilm formation, and adhesin expression compared to nonaggregative isolates (1, 11, 14, 17, 32).”
BackgroundWall, G., Herrera, N., & Lopez-Ribot, J. L. (2019) · Journal of Fungi · doi:10.3390/jof5040092 · Cited by 58
Self-citation
Metadata
- Authors
- Wall, G., Chaturvedi, A. K., Wormley, F. L., Wiederhold, N. P., Patterson, H. P., Patterson, T. F., & Lopez-Ribot, J. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-10
- Volume
- 62
- Issue
- 10
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2885698573
- Cited by
- 88
- References
- 18
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.